AR091490A1 - Antagonistas de iap - Google Patents

Antagonistas de iap

Info

Publication number
AR091490A1
AR091490A1 ARP130102157A AR091490A1 AR 091490 A1 AR091490 A1 AR 091490A1 AR P130102157 A ARP130102157 A AR P130102157A AR 091490 A1 AR091490 A1 AR 091490A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
alkyl
cycloalkyl
compounds
substituted alkyl
Prior art date
Application number
Other languages
English (en)
Inventor
S Kyoung Kim
M Borzilleri Robert
M Stang Erik
L Perez Heidi
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR091490A1 publication Critical patent/AR091490A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos que modulan la actividad de los inhibidores de la actividad de la apoptosis (IAP), composiciones farmacéuticas que contienen esos compuestos y métodos para tratar trastornos proliferativos y trastornos de apoptosis desregulada, tal como cáncer, mediante el uso de los compuestos de la presente. Reivindicación 1: Un compuesto caracterizado por la fórmula (1) en donde X es un enlace directo, -NH-, -O-, -NHCO- o -CONH-; R¹ es alquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido o arilo opcionalmente sustituido; R² es alquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, tioalquilo opcionalmente sustituido, cicloalquilalquilo opcionalmente sustituido, heterociclilo opcionalmente sustituido, arilalquilo opcionalmente sustituido o arilo opcionalmente sustituido; R³ y R⁴ son independientemente alquilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, heterociclilo opcionalmente sustituido, arilalquilo opcionalmente sustituido, heteroarilalquilo opcionalmente sustituido o heterocicloalquilo opcionalmente sustituido; R⁵ y R⁶ son independientemente hidrógeno, alquilo opcionalmente sustituido o cicloalquilo opcionalmente sustituido; R⁷ y R⁸ son independientemente hidrógeno o alquilo opcionalmente sustituido; o una sal, un tautómero o un estereoisómero de aquel aceptables desde el punto de vista farmacéutico.
ARP130102157 2012-06-19 2013-06-18 Antagonistas de iap AR091490A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661460P 2012-06-19 2012-06-19
US201361787808P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
AR091490A1 true AR091490A1 (es) 2015-02-11

Family

ID=48699353

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102157 AR091490A1 (es) 2012-06-19 2013-06-18 Antagonistas de iap

Country Status (6)

Country Link
US (1) US8889712B2 (es)
EP (1) EP2861581B9 (es)
AR (1) AR091490A1 (es)
TW (1) TW201402613A (es)
UY (1) UY34863A (es)
WO (1) WO2013192286A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2897949B1 (en) * 2012-09-18 2018-01-10 Bristol-Myers Squibb Company Iap antagonists
WO2015006524A1 (en) * 2013-07-12 2015-01-15 Bristol-Myers Squibb Company Iap antagonists
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
JP6953435B2 (ja) * 2016-05-09 2021-10-27 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二量体化合物
EA038128B1 (ru) 2016-09-15 2021-07-09 Бёрингер Ингельхайм Интернациональ Гмбх Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
CN110944719A (zh) * 2017-07-25 2020-03-31 合帕吉恩治疗公司 凋亡蛋白的二聚肽抑制剂
AU2019309942A1 (en) * 2018-07-23 2021-02-18 Ohio State Innovation Foundation Derivatives of papaverine that are effective hypoxic tumor radiosensitizers
US11807641B2 (en) * 2019-12-04 2023-11-07 Omeros Corporation MASP-2 inhibitors and methods of use
WO2021113690A1 (en) 2019-12-04 2021-06-10 Omeros Corporation Masp-2 inhibitors and methods of use
JP2023504541A (ja) 2019-12-04 2023-02-03 オメロス コーポレーション Ｍａｓｐ－２阻害剤および使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212157A (en) 1989-06-06 1993-05-18 Bio-Mega, Inc. Enzyme inhibitors
WO2009136290A1 (en) 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
WO2013071027A1 (en) 2011-11-09 2013-05-16 Ensemble Therapeutics Macrocyclic compounds for inhibition of inhibitors of apoptosis
WO2013071039A1 (en) 2011-11-09 2013-05-16 Ensemble Therapeutics Macrocyclic compounds for inhibition of inhibitors of apoptosis
US20140309265A1 (en) 2011-11-09 2014-10-16 Ensemble Therapeutics Macrocyclic compounds for inhibition of inhibitors of apoptosis

Also Published As

Publication number Publication date
WO2013192286A1 (en) 2013-12-27
US8889712B2 (en) 2014-11-18
EP2861581B9 (en) 2017-08-30
UY34863A (es) 2013-12-31
EP2861581B1 (en) 2017-02-01
TW201402613A (zh) 2014-01-16
US20130338081A1 (en) 2013-12-19
EP2861581A1 (en) 2015-04-22

Similar Documents

Publication Publication Date Title
AR091490A1 (es) Antagonistas de iap
DOP2018000187A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
AR102204A1 (es) Compuestos derivados de amino-alquilbenzotiazepinas
MX352672B (es) Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
PE20171177A1 (es) Compuestos aminopirimidinilo inhibidores de jak
AR113299A1 (es) Compuestos de isoindolina
CO2020000194A2 (es) Inhibidores de quinasa alk2 que contienen imidazol
AR095347A1 (es) Compuestos orgánicos
MX2015012427A (es) Compuestos de morfolinona de acido heteroarilo como inhibidores mdm2 para el tratamiento de cancer.
AR090005A1 (es) Imidazo[1,2-a]pirimidinas y piridinas sustituidas
AR084553A1 (es) DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER
EA201692114A1 (ru) Замещенные дигидроизохинолиноновые соединения
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
AR100806A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
AR093937A1 (es) Compuestos quimicos
AR103232A1 (es) ANTAGONISTAS DE TGFbR
CO6230986A2 (es) Compuesto de 4-piridinona y su uso para cancer
AR088246A1 (es) Derivados de etinilo
CL2019000662A1 (es) Inhibidores de dopamina–b–hidroxilasa.
BR112014030720A2 (pt) inibidores de fbxo3
PE20181017A1 (es) Compuestos heteroarilo y su uso como farmacos terapeuticos
MX362896B (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer.

Legal Events

Date Code Title Description
FB Suspension of granting procedure